Open AccessHighly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
Author(s) -
Sarah Palmer,
Robert W. Shafer,
Thomas C. Merigan
Publication year - 1999
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-199904160-00006
Subject(s) - drug resistance , virology , reverse transcriptase , drug , virus , biology , medicine , protease , microbiology and biotechnology , pharmacology , polymerase chain reaction , enzyme , genetics , gene , biochemistry
To assess the in-vitro drug susceptibility of a panel of five well-characterized drug-resistant HIV variants to recently developed anti-HIV compounds including seven reverse transcriptase (RT) inhibitors and seven protease inhibitors.